ASCO GU 2018: Debate: Is there Evidence for Local treatment in Patients with Newly Diagnosed Metastatic Disease?
San Francisco, CA (UroToday.com) The management of metastatic prostate cancer has changed dramatically over the last 10 years. Historically the treatment options for patients with metastatic prostate cancer was limited to hormonal therapy. Advances in nuclear medicine techniques have caused a stage migration towards low volume metastatic disease, in many cases oligometastatic disease, raising the questions if local and metastatic directed therapy (MDT) is prudent in this patient population.
ASCO GU 2018: Impact Of Statins On Outcomes In Patients With mCRPC: COU-AA-301 and COU-AA-302 Trials
San Francisco, CA (UroToday.com) Retrospective database studies have suggested that statins may have a chemo-preventative impact on metastatic castrate resistant prostate cancer (mCRPC) pts treated with prednisone (P)/abiraterone (AA).
ASCO GU 2018: Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes
San Francisco, CA (UroToday.com) Ongoing studies are evaluating the role of definitive treatment of the primary tumor in men with de novo metastatic prostate cancer. If proven beneficial, the optimal timing of the intervention will need to be considered. Little is known regarding the safety and quality of life outcomes of RP in metastatic castration resistant PCa (mCRPC).
ASCO GU 2018: Pembrolizumab for Recurrent or Advanced Prostate Cancer
San Francisco, CA (UroToday.com) Two previous Phase II trials studying pembrolizumab (Pembro) in 38 patients suggest that it may have a beneficial effect on prostate cancer (PC).
ASCO GU 2018: Effects Of a 6-month Moderate-intensity Exercise Program on Metabolic Parameters and Bone Mineral Density in Men on Androgen Deprivation Therapy for Prostate Cancer
San Francisco, CA (UroToday.com) Androgen deprivation therapy (ADT) is commonly used to treat prostate cancer (PC) but is associated with significant side effects including metabolic abnormalities and bone loss. Although multiple trials have demonstrated that exercise is associated with improvements in associated multiple side effects caused by ADT, its effects on metabolic and skeletal outcomes is unclear.
ASCO GU 2018: Outcomes in Patients with Advanced Prostate Cancer And Inactivating Germline Mutations in BRCA2 or ATM
San Francisco, CA (UroToday.com) Germline mutations in homologous recombination repair (HRR) genes, including BRCA2, are prevalent in 6-12% of pts with metastatic castration-resistant prostate cancer (mCRPC). BRCA2 germline mutations are associated with high-grade, early onset, and poor-prognosis localized disease, while outcomes in pts with advanced prostate cancer continue to be defined.
ASCO GU 2018: Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality
San Francisco, CA (UroToday.com) Dr. Kim Chi gave an excellent talk on the incorporation of genomics into the management of systemic therapy. Dr. Chi began his presentation with stating some key points. Genomic profiling of castrate resistant prostate cancer (CRPC) tissues reveals driver aberrations that are clinically relevant. Circulating tumor DNA (ct DNA) is an effective tool to identify mutations and copy number changes in men with CRPC. Deleterious genomic alterations have been associated with treatment outcomes and have the potential to inform patient management. The challenge is to find the next best treatment for patients entering the CRPC state.